|Chemical and physical data|
|Molar mass||191.27 g·mol−1|
|3D model (JSmol)|
5-MAPDB (1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine) is a chemical compound which might be an entactogenic drug. It is structurally related to drugs like 5-APDB and 5-MAPB, which have similar effects to MDMA and have been used as recreational drugs. 5-MAPDB has been studied to determine its pharmacological activity, and was found to be a relatively selective serotonin releaser, though with weaker actions as a releaser of other monoamines and 5-HT2 receptor family agonist, similar to older compounds such as 5-APDB.
5-MAPDB was banned in the UK in June 2013 as a temporary class drug along with 9 other related compounds, despite having never been sold as a street drug itself. This was due to concerns that it would have similar effects to drugs such as 5-APB that had been widely sold already, and 5-MAPDB might therefore be likely to become used recreationally also, if it were not banned preemptively.
- Rickli, A; Kopf, S; Hoener, MC; Liechti, ME (Jul 2015). “Pharmacological profile of novel psychoactive benzofurans”. British Journal of Pharmacology. 172 (13): 3412–25. doi:10.1111/bph.13128. PMC 4500375. PMID 25765500.
- Monte AP; Marona-Lewicka D; Cozzi NV; Nichols DE (November 1993). “Synthesis and pharmacological examination of benzofuran, indan, and tetralin analogues of 3,4-(methylenedioxy)amphetamine”. Journal of Medicinal Chemistry. 36 (23): 3700–6. doi:10.1021/jm00075a027. PMID 8246240.
- “Temporary class drug order report on 5-6APB and NBOMe compounds”. UK Home Office. 4 Jun 2013. Retrieved 2013-07-11.
(and close relatives)